Grammar:		DataElement 5.0
Namespace:		shr.oncology
Description:	"SHR implementation of ASCO requirements."
Uses:  			shr.core, shr.base, shr.condition, shr.lab, shr.observation, shr.procedure, shr.adverse, shr.medication, shr.assessment

CodeSystem:     SCT = http://snomed.info/sct
CodeSystem:     LNC = http://loinc.org
CodeSystem:		MTH = http://ncimeta.nci.nih.gov
CodeSystem:     UCUM = http://unitsofmeasure.org
CodeSystem:		HGNC = http://www.genenames.org


EntryElement:	BreastCancer
Concept:		MTH#C1446377
Based on:		Condition
Description:	"Finding or diagnosis of cancer originating in the tissues of the breast, and potentially spread to other organs of the body."
Value:			CodeableConcept from BreastCancerTypeVS
				Category includes #disease
0..1			Stage from urn:oid:2.16.840.1.113883.11.20.11.12


EntryElement:	TNMStage
Based on:		Observation
Concept:		LNC#21908-9
Description:	"The stage of a cancer, assessed according to the standard established by American Joint Committee on Cancer (AJCC). TNM Stage Grouping categorizes the progression of cancer using the Roman Numeral system. See Table 140 in HL7 CDA速 R2 Implementation Guide: Clinical Oncology Treatment Plan and Summary, Release 1 - US Realm"
Value:			CodeableConcept from urn:oid:2.16.840.1.113883.11.20.11.12  // or normative answer group LNC#LL240-3
				QuestionCode is LNC#21908-9 "Stage group.clinical Cancer"
1..1			FindingMethod from StagingMethodVS
0..1			StagingTiming
Components.ObservationComponent
includes 1..1 	T-Stage
includes 1..1 	N-Stage
includes 1..1 	M-Stage

		Element:		StagingSystem
		Concept:		TBD
		Description:	"What staging system are used "
		Value:			string  //TODO: is there a way to code this?
		0..1			Version

		Element:		StagingTiming  // TODO: this is not a time, but rather an event. The name should reflect that
		Concept:		TBD
		Description:	"Indicates when the staging was done, in terms of treatment landmarks, for example, at diagnosis (clinical), at surgery(pathologic), after treatment (post-neoadjuvant), at entry to a clinical trial, or at recurrence."
		Value:			CodeableConcept from StagingTimeVS
		// TODO: do we want to have a boolean indicating if this is the initial staging or a restaging?

		Element:		T-Stage
		Concept:		LNC#59528-0
		Based on:		ObservationComponent
		Description:	"The size and extent of the primary tumor (greatest dimension), based on criteria from the American Joint Committee on Cancer. See Table 152 in HL7 CDA速 R2 Implementation Guide: Clinical Oncology Treatment Plan and Summary, Release 1 - US Realm"
		Value:			CodeableConcept from urn:oid:2.16.840.1.113883.11.20.11.13

		Element:		N-Stage
		Concept:		LNC#59525-6
		Based on:		ObservationComponent
		Description:	"The presence of metastases in regional lymph nodes. TNM node category for staging derived from the American Joint Committee on Cancer. See Table 147 in HL7 CDA速 R2 Implementation Guide: Clinical Oncology Treatment Plan and Summary, Release 1 - US Realm"
		Value:			CodeableConcept from urn:oid:2.16.840.1.113883.11.20.11.14

		Element:		M-Stage
		Concept:		LNC#59522-3
		Based on:		ObservationComponent
		Description:	"Part of the TNM classification system representing metastases.  The system is used to describe the spread of cancer to other parts of the body. See Table 144 in HL7 CDA速 R2 Implementation Guide: Clinical Oncology Treatment Plan and Summary, Release 1 - US Realm"
		Value:			CodeableConcept from urn:oid:2.16.840.1.113883.11.20.11.25


EntryElement:	HistologicGrade
Concept:		MTH#C1511980
Based on:		Observation
Description:	"The Elston Grade/Nottingham Score, representative of the aggressive potential of the tumor. Well differentiated (Grade 1) look similar to normal cells and are usually slow growing, while poorly differentiated cells (Grade 3) look very different than normal and are fast-growing."
Value:		CodeableConcept from NottinghamCombinedGradeVS
			Components.ObservationComponent
			includes 0..1 TubuleFormationScore
			includes 0..1 NuclearPleomorphismScore
			includes 0..1 MitoticCountScore

			Element:		TubuleFormationScore
			Concept:		SCT#371470008
			Based on:		ObservationComponent
			Description:	"A comparison between structures formed by the tumor cells as opposed to those formed by normal cells. Scored 1 to 3 with 3 being the most abnormal."
			Value:			CodeableConcept from TubuleFormationScoreVS  //TODO: Determine if it is better to use codes as opposed to a number 1, 2 or 3. Observations don't support integer or posInteger

			Element:		NuclearPleomorphismScore
			Concept:		TBD
			Based on:		ObservationComponent
			Description:	"How large and varied the nuclei of the tumor cells are. Scored 1 to 3, with 3 being the most pleomorphism."
			Value:			CodeableConcept from NuclearPleomorphismScoreVS

			Element:		MitoticCountScore
			Concept:		SCT#371472000
			Based on:		ObservationComponent
			Description:	"How fast the tumor cells are growing and dividing, determined from the number of mitotic cells present. Scored 1 to 3, with 3 being the most mitotic cells."
			Value:			Quantity   // 1 to 3


EntryElement:	ReceptorStatusObservation
Concept:		MTH#C0449443
Based on:		Observation
Description:	"Refers to the presence or absence of specific receptor molecules on the surface of a cells in a specimen."
Value:			CodeableConcept from PositiveNegativeVS
1..1			ReceptorType
				Components.ObservationComponent
				includes 0..1			ReceptorPositivityPercentage
				includes 0..1			ReceptorAllredTotalScore
				includes 0..1			ReceptorProportionScore
				includes 0..1			ReceptorIntensityScore

		Element:		ReceptorType
		Concept:		MTH#C0597357 //or SCT#116647005
		Description:	"A protein located on the cell surface, or in the cytoplasm, that binds to a specific signaling factor, such as a hormone, antigen, or neurotransmitter, causing a conformational and functional change in the receptor molecule. The ligand-bound receptor then alters its interaction with target molecules, which leads to changes in cellular physiology through modification of the activity of one or more signal transduction pathways."
		Value:			CodeableConcept from ReceptorVS

		Element:		ReceptorPositivityPercentage
		Based on:		ObservationComponent
		Concept:		TBD
		Description:	"The percentage of cells that test (stain) positive for the presence of a receptor."
		Value:			Quantity with units UCUM#%

		Element:		ReceptorProportionScore
		Concept:		TBD
		Based on:		ObservationComponent
		Description:	"Part of Allred scoring, based on the percentage of cells that stain for a receptor, on a scale of 0 to 5."
		Value:			Quantity // unsignedInt limit to maximum value of 5

		Element:		ReceptorIntensityScore
		Concept:		TBD
		Based on:		ObservationComponent
		Description:	"Part of the Allred scoring, based on the intensity of that staining, on a scale of 0 to 3."
		Value:			Quantity  // TODO: unsignedInt limit to max of 3

		Element:		ReceptorAllredTotalScore
		Concept:		TBD
		Based on:		ObservationComponent
		Description:	"Part of the Allred scoring, the total of proportion and intensity scores, from 0 to 8."
		Value:			Quantity // unsignedInt -  limit to max of 8


EntryElement:	BreastCancerReceptorStatus
Based on:		Panel
Concept:		TBD
Description:	"Immunohistochemistry (IHC) assessment for estrogen receptor (ER) and progesterone receptor (PR) as well as IHC or in situ hybridization (ISH) determination of human epidermal growth factor receptor 2 (HER2) status"
			QuestionCode is TBD#TBD
			Members.Finding
			includes 0..1 EstrogenReceptorStatus
			includes 0..1 ProgesteroneReceptorStatus
			includes 0..1 HumanEpiduralGrowthFactorReceptor2Status

			EntryElement:	EstrogenReceptorStatus
			Based on:		ReceptorStatusObservation
			Concept:		TBD
			Description:	"Estrogen receptor alpha is the predominant estrogen receptor expressed in breast tissue and is overexpressed in around 50% of breast carcinomas. ER status (positive=present or overexpressed; negative=absent) is a factor in determining prognosis and treatment options."
							QuestionCode is LNC#16112-5
							ReceptorType is SCT#23307004

			EntryElement:	ProgesteroneReceptorStatus
			Based on:		ReceptorStatusObservation
			Concept:		MTH#C1514471
			Description:	"Progesterone receptor is expressed in 65% of breast carcinomas. PR status (positive=present or overexpressed; negative=absent) is a factor in determining prognosis and treatment options."
							QuestionCode is LNC#16113-3
							ReceptorType is MTH#C0034833

			EntryElement:	HumanEpiduralGrowthFactorReceptor2Status
			Based on:		ReceptorStatusObservation
			Concept:		MTH#C3810543
			Description:	"HER2 is a member of the human epidermal growth factor receptor family of proteins and is encoded by the ERBB2 oncogene. HER2 is overexpressed in 20-30% of breast tumors,10 and is associated with an aggressive clinical course and poor prognosis. HER2 status (positive=present or overexpressed; negative=absent) is a factor in determining prognosis and treatment options."
							QuestionCode is LNC#48676-1
							ReceptorType is TBD#TBD
							FindingMethod from HER2MethodVS   // this is the grammar for restricting a value to a value set

EntryElement: 	TumorProperties
Based on:	Observation
Concept:	MTH#C4086369
Description:	"Measurement of the longest diameter of a tumor, in situ or on a excised tumor. See CDISC Table 3.3.2"
Value:		Quantity with units UCUM#mm
			Components.ObservationComponent
			includes 0..1	TumorPrimaryDimensionSize
			includes 0..1	TumorSecondaryDimensionSize
			includes 0..1	SizeOfGrossTumorBed
			includes 0..1	TumorMargins
			includes 0..1	Cellularity   // not sure this belongs here
			includes 0..1	PercentageInSituCarcinoma   // not sure this belongs here
			// Do we need to record the method? whether the result of imaging, or study of a removed tumor after lumpectomy?

		Element:		TumorPrimaryDimensionSize
		Description:	"The longest diameter of the primary tumor."
		Based on:		ObservationComponent
		Concept:		TBD
		Value:			Quantity with units UCUM#mm		
		
		Element:		TumorSecondaryDimensionSize
		Description:	"The longest perpendicular diameter of the primary tumor."
		Based on:		ObservationComponent
		Concept:		TBD
		Value:			Quantity with units UCUM#mm

		Element:		SizeOfGrossTumorBed
		Based on:		ObservationComponent
		Concept:		TBD
		Description:	"The largest dimension of the gross tumor bed/fibrotic area."
		Value:			Quantity with units UCUM#mm

		Element: 		TumorMargins
		Concept:		MTH#C126983
		Based on:		ObservationComponent
		Description:	"The edge or border of the tissue removed in cancer surgery. The margin is described as negative or clean when the pathologist finds no cancer cells at the edge of the tissue, suggesting that all of the cancer has been removed. The margin is described as positive or involved when the pathologist finds cancer cells at the edge of the tissue, suggesting that all of the cancer has not been removed."
		Value:			CodeableConcept from PositiveNegativeVS

		Element:		TumorMarginDescription
		Concept:		TBD
		Based on:		ObservationComponent
		Description:	"Description of the edge or border of tumor in situ by radiologist or of removed tumor by pathologist."
		Value:			CodeableConcept from TumorMarginDescriptionVS

		Element:		Cellularity
		Concept:		MTH#C4055283
		Based on:		ObservationComponent
		Description:	"Percentage of cells in a sample that are cancerous"
		Value:			Quantity with units UCUM#%

		Element:		PercentageInSituCarcinoma
		Based on:		ObservationComponent
		Concept:		TBD
		Description:	"The percentage of the cancer that is in situ, as opposed to invading other tissues."
		Value:			Quantity with units UCUM#%


EntryElement:		NoLymphaticInvolvement		
Based on:			ConditionAbsent
Concept:			TBD
Description:		"Lymph nodes in all, or certain part, of the lymphatic system do not contain cancer cells."
Value:				CodeableConcept is MTH#C0746333
1..1				BodySite from LymphSystemSubdivisionVS
	
EntryElement:		LymphaticInvolvement
Based on:			Observation
Concept:			MTH#C0746333
Description:		"Description of lymph nodes contain cancer cells."
Value:				CodeableConcept from PositiveNegativeVS
1..1				BodySite from LymphSystemSubdivisionVS 
					Components.ObservationComponent
					includes 0..1 LargestLymphNodeSize
					includes 0..1 NumberOfLymphNodesInvolved
					includes 0..1 DegreeOfLymphaticInvolvement

		Element:		LargestLymphNodeSize
		Based on:		ObservationComponent
		Concept:		MTH#C1285847
		Description:	"The largest dimension of the largest lymph node invaded by cancer cells."
		Value: 			Quantity with units UCUM#mm
						

		Element:		NumberOfLymphNodesInvolved
		Based on:		ObservationComponent
		Concept:		TBD
		Description:	"A count of lymph nodes invaded by cancer cells of those examined."
		Value:			Quantity with units UCUM#1 "Count"

		Element:		DegreeOfLymphaticInvolvement
		Based on:		ObservationComponent
		Concept:		TBD
		Description:	"Assessment of how much cancer is in a lymph node."
		Value:			CodeableConcept from DegreeOfLymphaticInvolvementVS

EntryElement:	CancerGrowthPotential
Description:	"Information relating to rate of cell growth or proportion of cancer cells within the tumor that are growing and dividing to form new cancer cells."
Concept:		MTH#C1516170 "Cancer Cell Growth"
Based on:		Observation
Value:			CodeableConcept from QualitativeValueScaleVS
				Components.ObservationComponent
				includes 0..1	Ki-67LabelingIndex
				includes 0..1	S-PhaseFraction

			Element: 		Ki-67LabelingIndex
			Based on:		ObservationComponent		
			Concept:		MTH#C4049944
			Description:	"Ki-67 is a protein phosphatase whose expression is strongly associated with cell proliferation and encoded by the MKI67 gene. The Ki67 labeling index is the fraction of Ki-67-positive cells to total cells in a tumor specimen and may be useful for determining prognosis with respect to survival and disease recurrence. The more positive cells there are, the more quickly they are dividing and forming new cells.	ReferenceRange: Low <10, Intermediate 10-20, >20 High"
			Value:		 	Quantity with units UCUM#%

			Element:		S-PhaseFraction
			Based on:		ObservationComponent
			Concept:		MTH#C0812425
			Description: "An expression of the number of mitoses found in a stated number of cells. The S-phase fraction number tells you what percentage of cells in the tissue sample are in the process of copying their genetic information (DNA). This S-phase, short for synthesis phase, happens just before a cell divides into two new cells. ReferenceRange: Low <6, Intermediate 6-10, >10 High."
			Value:			Quantity with units UCUM#%

Element:		GeneticVariant
Based on:		Finding
Concept:		MTH#C0678941
Description:	"Whether the patient carries a mutation in a particular gene."
Value:			CodeableConcept from PositiveNegativeVS
1..1			GeneIdentifier
0..1			Refseq

			Element:		GeneIdentifier
			Concept:		MTH#C1706509
			Description:	"A unique code for a gene, including protein coding genes, ncRNA genes and pseudogenes, to allow unambiguous communication, drawn from HUGO Gene Nomenclature Committee."
			Value:			CodeableConcept from GeneIdentifierVS

			Element:		Refseq
			Concept:		TBD
			Description:	"The Reference Sequence (RefSeq) collection provides a comprehensive, integrated, non-redundant, well-annotated set of sequences, including genomic DNA, transcripts, and proteins. RefSeq sequences form a foundation for medical, functional, and diversity studies. They provide a stable reference for genome annotation, gene identification and characterization, mutation and polymorphism analysis (especially RefSeqGene records), expression studies, and comparative analyses."
			Value: 			CodeableConcept from RefseqVS

EntryElement:	BreastCancerGeneticAnalysis
Concept:	TBD
Based on:	Panel  // just a grouping of results
Description:	"The status of genes known or suspected to play a role in breast cancer risk, for example, the tumor suppressor genes, BRCA1 and BRCA2."
			Members.Finding
			includes 1..1			ref(BRCA1Variant)
			includes 1..1			ref(BRCA2Variant)

	Element:		BRCA1Variant
	Concept:		TBD
	Based on:		GeneticVariant
	Description:	"Whether the patient has a mutation in the BRCA1 gene."
	Value:			CodeableConcept from PositiveNegativeVS
					GeneIdentifier is HGNC#BRCA1

	Element:		BRCA2Variant
	Concept:		TBD
	Based on:		GeneticVariant
	Description:	"Whether the patient has a mutation in the BRCA2 gene."
	Value:			CodeableConcept from PositiveNegativeVS
					GeneIdentifier is HGNC#BRCA2

EntryElement:	Progression
Based on:		EvaluationResult
Concept:		MTH#C0449258
Description:	"A finding related to the current trend of a disease. This concept is most often used for chronic and incurable diseases where the status and trendline of the disease is an important determinant of therapy and prognosis. The specific disorder being evaluated must be cited in the AssessmentFocus as a reference to a Condition."
Value:			CodeableConcept from SubjectiveProgressionVS
				Category includes MTH#C0421176 "Efficacy"
				Subject value is type ref(BreastCancer)
1..1			QuestionCode is MTH#C0421176 "Progression"
0..*			Evidence from ProgressionEvidenceTypeVS


/*
FHIR Genomics:
https://www.hl7.org/FHIR/2016Jan/obs-genetics-example3-bcr1%20and%20bcr2%20sequencing%20with%20FamilyHistory%20-1.json.html
https://www.hl7.org/FHIR/2016Jan/observation-genetics-cg-prf-1a.html
https://www.hl7.org/FHIR/2016Jan/observation-genetics.html
https://www.hl7.org/FHIR/2016Jan/obs-genetics-example2-germline.html
*/